Source: The Paper
Before waiting for the official news of the tenth batch of drug centralized procurement, the industry first waited for the old matter of centralized procurement bidding announced by the Joint Procurement Office.
On April 17, Shanghai Sunshine Pharmaceutical Procurement Network issued the "Announcement on Interviewing Enterprises Bidding Enterprises with Abnormal Prices of Some Varieties of Drugs Organized by the State" by the National Drug Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office").
According to the announcement, recently, some people have reported that four varieties of bromhexine injection, octreotide injection, piperacillin-tazobactam injection, and glycerol fructose sodium chloride injection have abnormal bidding prices in the centralized procurement of drugs organized by the state. The Joint Procurement Office attaches great importance to the report clues, and is scheduled to interview all bidders of the above four varieties from April 18 to 19, and ask the relevant enterprises to cooperate.
Since the centralized procurement of drugs in the "4+7" pilot cities in 2018, 9 batches of centralized drug procurement organized by the state have been completed. The four products named in the above announcement are all injections, which appeared in the seventh, eighth and ninth batches of centralized procurement respectively, and are counted according to the list of winning bidders, involving a total of 28 companies. Many companies under the listed pharmaceutical companies of the bid-winning enterprises, including Poinsettia (300723), Humanwell Pharmaceutical (600079), North China Pharmaceutical (600812), China National Pharmaceutical (600056), and Federal Pharmaceutical (3933.HK). HK), Jincheng Pharmaceutical (300233), Kangenbei (600572), Jinyao Pharmaceutical (600488), etc.
Bid-winning information for bromhexine injection
Octreotide injection bid information
Specifically, the expectorant drug bromhexine injection and octreotide injection for the treatment of acromegaly and other diseases are the seventh batch of centralized procurement varieties, according to the results announced in July 2022, there are 4 winning bidders for bromhexine injection, including Shijiazhuang No. 4 Pharmaceutical Co., Ltd., Guangzhou Poinsettia Pharmaceutical Co., Ltd. (Hebei Kaiwei Pharmaceutical Co., Ltd. is entrusted to produce), Renhe Yikang Group Co., Ltd. (Hebei Renhe Yikang Pharmaceutical Co., Ltd. is entrusted to produce) and Chengdu Xinjie High-tech Development Co., Ltd. (Sichuan Meida Kangjiale Pharmaceutical Co., Ltd. is entrusted to produce).
There are 8 winning bidders for octreotide injection, including Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd., Sinopharm Yixin Pharmaceutical Co., Ltd., Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical Co., Ltd., Benxi Hengkang Pharmaceutical Co., Ltd., Chengdu Shengnuo Biopharmaceutical Co., Ltd., Wuhan Renfu Pharmaceutical Co., Ltd. and Hainan Zhonghe Pharmaceutical Co., Ltd.
Piperacillin tazobactam injection bid winning information
Piperacillin tazobactam injection is an antibiotic, which is the eighth batch of centralized procurement varieties, with a total of 9 winning bidders, including Shandong Anxin Pharmaceutical Co., Ltd., North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. (North China Pharmaceutical Co., Ltd. entrusted production), Hainan General Sanyo Pharmaceutical Co., Ltd., Zhuhai Federal Pharmaceutical Co., Ltd. Zhongshan Branch, Suzhou Erye Pharmaceutical Co., Ltd. (Shandong Erye Pharmaceutical Co., Ltd. entrusted production), Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. (Shandong Anxin Pharmaceutical Co., Ltd. entrusted production), Jiangsu Haihong Pharmaceutical Co., Ltd., Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. and Ruiyang Pharmaceutical Co., Ltd.
Winning information of glycerol fructose sodium chloride injection
Fructose Sodium Chloride Injection is a drug that reduces intracranial pressure, which is the ninth batch of centralized procurement varieties, and 7 pharmaceutical companies have won the bid, including Chenxin Pharmaceutical Co., Ltd., Shandong Qidu Pharmaceutical Co., Ltd., Hainan Beite Pharmaceutical Co., Ltd. (Sichuan Pacific Pharmaceutical Co., Ltd. entrusted to produce), Huaren Pharmaceutical (Rizhao) Co., Ltd., Huaxia Shengsheng Pharmaceutical (Beijing) Co., Ltd., Beijing Bulin Biotechnology Co., Ltd. (Chifeng Yuansheng Pharmaceutical Co., Ltd. entrusted to produce) and Hubei Jinyao Pharmaceutical Co., Ltd.
It should be noted that the announcement particularly emphasizes that all bidding enterprises of 4 varieties will be interviewed. This means that the number of companies interviewed this time will also include pharmaceutical companies that participated in the bidding but did not win the bid, and the number will be greater than 28.
According to the announcement, what was reported this time was that there was an abnormal bidding price in the centralized procurement of drugs organized by the state. Generally speaking, the bidding documents of centralized procurement put forward compliance requirements for the participating bidding enterprises. Taking the ninth batch of centralized procurement as an example, the commitment letter mentions that we promise that we have no interest relationship with the joint procurement office, will not make any improper contact with the purchaser in order to achieve this project, will not collude with other enterprises to declare and negotiate quotations, will not have a direct holding and management relationship with other enterprises of the same variety or the person in charge of the enterprise is the same person, will not interfere with the work order related to centralized procurement, and will not have any violations of laws and regulations in the declaration process.
The bidding documents of the ninth batch of centralized procurement also mentioned that if the declaring enterprises, the selected enterprises, and the distribution enterprises have any of the following behaviors, they will be included in the "violation list" if the relevant departments determine that the circumstances are serious, including collusion with each other to declare and negotiate quotations, exclude the fair competition of other declaring enterprises, and damage the legitimate interests of the purchaser or other declaring enterprises.